About - CrossBridge
CrossBridge is on a mission to help achieve the best outcomes at the lowest possible cost for all chronic inflammatory and autoimmune disease. CrossBridge resulted from the vision of Bill Conlan, who has deep experience in the application of the latest technologies to meet challenges in healthcare. Bill’s resolve to attack chronic inflammatory disease comes from his own experience with ankylosing spondylitis.
Bill Conlan, Susan Spalding, Bruce Freundlich MD
page-template,page-template-full_width,page-template-full_width-php,page,page-id-13822,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive


Your Mission Is Our Mission: To Achieve the
Best Outcomes at the Lowest Cost.

Bill Conlan

Chief Executive Officer

Bill has a 27-year history of employing the latest technologies to meet challenges in health care.  Most recently, Bill co-founded HealthQx, a value-based payment analytics company relied on by payers with 45 million total members. HealthQx was acquired by McKesson in 2016, and renamed Change Healthcare. Read More. Previously, Bill founded Healthcare Data Management (HDM), a pioneer in modeling employee health benefit plans and using data-driven metrics to monitor health plan spend.  HDM was acquired by Thomson Reuters in 2010 and is now part of IBM Watson. CrossBridge is a mission for Bill, who has ankylosing spondylitis.  He also has family members with rheumatoid arthritis and multiple sclerosis.

Susan Spalding

Chief Operating Officer

Susan co-founded Eviti, Inc., which became the leading oncology decision-support platform and healthcare payer reimbursement SaaS-based platform in the U. S.  The platform connects providers and payers at the critical moments of clinical need. Treatment plan data is shared in real time, connecting all pertinent stakeholders for appropriate reimbursement and optimal patient management.   The Eviti customer base includes national and regional payers with 30 million members across all lines of medical health insurance  – fully insured, self-insured, Medicare, Medicaid, Federal government plans and TPAs.  The platform was adopted by payers and associated provider networks in all 50 states.

Bruce Freundlich, MD

Chief Medical Officer

Dr. Bruce Freundlich is skilled in clinical research and medical affairs, with expertise in Rheumatology, Dermatology, Endocrinology and Neuro-psychiatry.  Dr. Freundlich was Senior Vice president, Medical at Antares Pharmaceuticals and Vice President Inflammation and Vice President, Global Medical Affairs at Pfizer Pharmaceuticals over a nine-year period. Among other accomplishments, he was responsible for post-marketing Enbrel trials. Dr. Freundlich also served as Chief of Clinical Rheumatology at the University of Pennsylvania for more than six years.

Clinical Advisory Board

Jeff Curtis 


Dr. Curtis is a rheumatologist and epidemiologist involved in the study of the comparative effectiveness and safety of medications used to treat rheumatoid arthritis and a well-known leader in the research of rheumatoid and psoriatic arthritis.  He is Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, and Co-Director of the UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders.  Dr. Curtis is the Co-PI of the Patient Powered Research Network, “Arthritis-Power” registry.  In 2015, he became a member of the FDA Arthritis Advisory Committee. He received his Medical Degree and an Master of Public Health (MPH) Degree, and completed a residency in internal medicine at Oregon Health & Sciences University. The focus of his  graduate studies at Stanford University was Clinical Informatics. He also received an M.S. degree in epidemiology at the Harvard School of Public Health.

Herbert Baraf


A nationally recognized authority on issues of rheumatology practice management, Dr. Baraf is a senior member and managing partner of Arthritis and Rheumatism Associates (ARA), the largest private practice rheumatology group in the U. S.  He founded The Center for Rheumatology and Bone Research, ARA’s research division, and has been principal investigator on over 350 clinical trials, studying new treatments for rheumatic disorders. He is a Clinical Professor of Medicine at George Washington University School of Medicine and Clinical Associate Professor of Medicine at the University of Maryland School of Medicine.  He received his B.S. Degree at the University of Michigan, a medical degree at S.U.N.Y. College of Medicine, completed Internal Medicine training at the George Washington University Hospital and a Fellowship in Rheumatology at Duke University Medical Center.